Posted by Michael Wonder on 15 Mar 2022
Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
15 March 2022 - Hansa Biopharma completes the AMNOG reimbursement process for Idefirix in Germany.
Hansa Biopharma today announces having reached an agreement on the reimbursement for Idefirix in Germany with the National Association of Statutory Health Insurance Funds, GKV-Spitzenverband effective March 15.
